Study protocol for the ABERRANT study: antibiotic-induced disruption of the maternal and infant microbiome and adverse health outcomes - a prospective cohort study among children born at term.

Détails

Ressource 1Télécharger: 32580987_BIB_41FCE96DFE45.pdf (605.86 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_41FCE96DFE45
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Study protocol for the ABERRANT study: antibiotic-induced disruption of the maternal and infant microbiome and adverse health outcomes - a prospective cohort study among children born at term.
Périodique
BMJ open
Auteur⸱e⸱s
Volery M., Scherz V., Jakob W., Bandeira D., Deggim-Messmer V., Lauber-Biason A., Wildhaber J., Falquet L., Curtis N., Zimmermann P.
ISSN
2044-6055 (Electronic)
ISSN-L
2044-6055
Statut éditorial
Publié
Date de publication
23/06/2020
Peer-reviewed
Oui
Volume
10
Numéro
6
Pages
e036275
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
There is compositional overlap between the maternal intestinal microbiome, the breast milk microbiome and the infant oral and intestinal microbiome. Antibiotics cause profound changes in the microbiome. However, the effect of intrapartum and early-life antibiotics on the maternal intestinal and breast milk microbiome, and the infant oral and intestinal microbiome, and whether effects are only short term or persist long term remain uncertain.
In this prospective cohort study, we will use metagenomic sequencing to determine: (1) the effect of intrapartum antibiotics on the composition of the breast milk, and the infant oral and intestinal microbiome, including the development and persistence of antibiotic resistance; (2) the effect of antibiotic exposure in the first year of life on the composition of the infant oral and intestinal microbiome, including the development and persistence of antibiotic resistance; (3) the effect of disruption of the infant oral and intestinal microbiome on health outcomes and (4) the compositional overlap between the maternal intestinal microbiome, the breast milk microbiome and the infant oral and intestinal microbiome.
The ABERRANT study has been approved by the commission cantonale d'éthique de la recherche sur l'être humain (CER-VD) du Canton de Vaud (#2019-01567). Outcomes will be disseminated through publication and will be presented at scientific conferences.
NCT04091282.
Mots-clé
Anti-Bacterial Agents/adverse effects, Clinical Protocols, Drug Resistance, Bacterial, Eczema/epidemiology, Female, Gastrointestinal Microbiome/drug effects, Gastrointestinal Microbiome/genetics, Gastrointestinal Microbiome/physiology, Humans, Hypersensitivity/epidemiology, Infant, Infant, Newborn, Metagenomics, Milk, Human/chemistry, Milk, Human/microbiology, Otitis Media/epidemiology, Pregnancy, Prenatal Exposure Delayed Effects/chemically induced, Prospective Studies, Respiratory Tract Diseases/epidemiology, immunology, microbiology, molecular diagnostics, neonatology, paediatric infectious disease & immunisation
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/07/2020 17:41
Dernière modification de la notice
09/08/2024 14:58
Données d'usage